Search Results

You are looking at 81 - 90 of 221 items for :

  • Refine by Access: Content accessible to Me x
Clear All
Full access

NCCN Guidelines Update: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Presented by: Deborah M. Stephens

leading to treatment discontinuation with zanubrutinib. One notable side effect of zanubrutinib was a tendency to cause more neutropenia, although this did not correlate to neutropenic fever or higher rates of grade 3 infections. “The findings of these 2

Full access

Sleep Disorders, Fatigue, and Cognitive Function in Cancer Survivors: A Plenary Session

Presented by: Kristin Dickinson, Halle C.F. Moore, Jennifer Schmitz, and Eric S. Zhou

Moderated by: Andrew T. Day

Center, University of Nebraska Medical Center, was 38 years old and a full-time nurse practitioner, wife, and active mother of 2 when she began experiencing recurrent infections. The infections led to constant fevers, bone pain, and mouth sores, and

Full access

Vaccinations for Patients With Cancer and Cancer Survivors

Presented by: Maria Alma Rodriguez

, and rubella (MMR), oral typhoid, yellow fever, rotavirus, nasal influenza, and varicella—are contraindicated or should be used with caution in actively immunocompromised cancer survivors and their close contacts. Per the NCCN Guidelines, live

Full access

Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma

Presented by: Natalie S. Callander

(84%), its severity was limited in most participants. “Patients typically develop a fever, chills, or changes in blood pressure within 24 hours of receiving idecabtagene vicleucel, but most are responsive to tocilizumab or steroids,” said Dr. Callander

Full access

Myeloproliferative Neoplasms: Emerging Treatment Options for Myelofibrosis

Presented by: Aaron T. Gerds

70% of patients have symptoms driven primarily by cytokines, such as fevers and night sweats. Many patients also experience cytopenias, particularly anemia and thrombocytopenia. 2 , 3 “And, of course, it is a disease that carries a shortened life

Full access

Diagnostic Strategies for Invasive Fungal Infections in Patients With Hematologic Malignancies and Hematopoietic Stem Cell Transplant Recipients

Maxim Norkin and John R. Wingard

disseminated infection less commonly seen. Candida infections of the mucosa occur early and throughout the course of neutropenia and/or immunosuppressive therapy. Candida fungemia is rarely the cause of first neutropenic fever, but may be a cause of

Full access

A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group

Gary H. Lyman and Marek S. Poniewierski

) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients . Support Care Cancer 2013 ; 21 : 1487 – 1495 . 43. Talcott JA Siegel RD Finberg R . Risk assessment in cancer patients with fever and

Full access

Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens in a Large Community-Based Oncology Practice

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page, and Chun Chao

defined using one of the following methods: (1) neutropenia (ICD-9 code 288.0) and fever (ICD-9 code 780.6) within 7 days of hospitalization; (2) absolute neutrophil count (ANC) <1,000/mcL and fever (ICD-9 code 780.6) within 7 days of hospitalization; (3

Full access

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology

Daniel A. Pollyea, Jessica K. Altman, Rita Assi, Dale Bixby, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Brian A. Jonas, Ashwin Kishtagari, Jeffrey Lancet, Lori Maness, James Mangan, Gabriel Mannis, Guido Marcucci, Alice Mims, Kelsey Moriarty, Moaath Mustafa Ali, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Alexander Perl, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi, Rory Shallis, Paul J. Shami, Eytan Stein, Richard M. Stone, Kendra Sweet, Swapna Thota, Geoffrey Uy, Pankit Vachhani, Carly J. Cassara, Deborah A. Freedman-Cass, and Katie Stehman

response was 5 months (range, 1–20+ months), with responses occurring in all sites of disease, including skin, bone marrow, and lymph nodes. Acute infusion-related adverse effects such as fever, chills, and nausea were mild to moderate in severity and were

Full access

New Agents in Metastatic Prostate Cancer

Atish D. Choudhury and Philip W. Kantoff

was accompanied by increased toxicity compared with mitoxantrone, with higher rates of grade 3 or greater neutropenia (82% vs. 58%), neutropenic fever (8% vs. 1%), and diarrhea (6% vs. <1%), along with greater requirements for dose reductions (12% vs